Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
SILIQ™
(brodalumab) Injection
WARNING
SUICIDAL IDEATION AND BEHAVIOR
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal ideation and behavior should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes [see WARNINGS AND PRECAUTIONS].
Because of the observed suicidal behavior in subjects treated with SILIQ, SILIQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SILIQ REMS Program [see WARNINGS AND PRECAUTIONS].
Brodalumab is a human monoclonal IgG2κ antibody directed against human interleukin-17 receptor A (IL-17RA). It is expressed in a Chinese Hamster Ovary (CHO) cell line. Brodalumab is comprised of 1312 amino acids and has an estimated molecular mass of 144,000 Daltons.
SILIQ (brodalumab) Injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution, delivered via subcutaneous injection. A few translucent to white, amorphous particles may be present. SILIQ is supplied in a single-dose 2.25 mL syringe made from type 1 glass with stainless steel 27G x ½” needle. Each SILIQ single-dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8.
SILIQ™ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
The recommended SILIQ dose is 210 mg administered by subcutaneous injection at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.
If an adequate response has not been achieved after 12 to 16 weeks of treatment with SILIQ, consider discontinuing therapy. Continued treatment beyond 16 weeks in patients who have not achieved an adequate response is not likely to result in greater success.
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SILIQ [see WARNINGS AND PRECAUTIONS].
Administer SILIQ subcutaneously. Each prefilled syringe is for single-dose only.
Instruct patients to review the Medication Guide before use (see Medication Guide). SILIQ is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SILIQ when deemed appropriate by a healthcare professional and after proper training in subcutaneous injection technique using the prefilled syringe.
Advise patients who are self-administering to inject the full dose and to read the Instructions for Use before administration (see Instructions for Use).
Do not inject SILIQ into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis.
Injection: 210 mg/1.5 mL solution in a single-dose prefilled syringe. SILIQ is a clear to slightly opalescent, colorless to slightly yellow solution and may contain a few translucent to white, amorphous particles .
SILIQ (brodalumab) Injection is available in a single-dose prefilled syringe containing a sterile, preservative-free clear to slightly opalescent, colorless to slightly yellow solution that may contain a few translucent to white, amorphous particles.
NDC 0187-0004-02: Carton of two 210 mg/1.5 mL single-dose prefilled syringes
Manufactured for: Valeant Pharmaceuticals North America LLC Bridgewater, NJ 08807 USA. Manufactured by: Valeant Pharmaceuticals Luxembourg S.à.r.l. Grand Duchy of Luxembourg, L-1931, Luxembourg. Revised: Feb 2017
The following serious adverse reactions are discussed in greater detail in other sections of labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The overall safety population included 4558 subjects (3066 SILIQ, 613 ustekinumab, 879 placebo) in controlled clinical trials and open-label extension studies. The majority of subjects were male (69%), white (91%), and aged 40-64 years old  (58%). One-third of subjects reported previous biologic use prior to enrollment. Across the clinical development program, 4464 subjects received at least one dose of SILIQ; 3755 subjects were exposed to SILIQ for at least 1 year.
Weeks 0 to 12: Data from one multicenter, randomized, placebo-controlled trial (Trial 1), two multicenter, randomized, placebo-and active-controlled trials (Trials 2 and 3), and one dose-finding trial (Trial 4) in plaque psoriasis were pooled to evaluate the safety of SILIQ (210 mg weekly at Weeks 0, 1, and 2, followed by treatments every 2 weeks [Q2W]) compared to placebo for up to 12 weeks after treatment initiation.
During the 12-week, randomized treatment period, about 1% of the subjects in the treatment groups (SILIQ, ustekinumab and placebo) discontinued treatment because of adverse events. Adverse events leading to discontinuation of SILIQ included neutropenia, arthralgia, and urticaria. The proportion of subjects who developed serious adverse events was similar among the SILIQ, ustekinumab, and placebo groups.
Table 1 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the SILIQ 210 mg Q2W group than in the placebo group during the 12-week randomized treatment period of the pooled trials.
Table 1: Adverse Reactions Occurring in ≥ 1% of
Subjects in the SILIQ Group and More Frequently than in the Placebo Group in Plaque
Psoriasis Trials through Week 12
| Adverse Reactions | Placebo (N=879) n (%) |
SILIQ 210 mg every 2 weeksa (N=1496) n (%) |
Ustekinumab (N=613)b n (%) |
| Arthralgia | 29 (3.3) | 71 (4.7) | 15 (2.4) |
| Headache | 31 (3.5) | 64 (4.3) | 23 (3.8) |
| Fatigue | 10 (1.1) | 39 (2.6) | 16 (2.6) |
| Diarrhea | 10 (1.1) | 33 (2.2) | 5 (0.8) |
| Oropharyngeal pain | 10 (1.1) | 31 (2.1) | 8 (1.3) |
| Nausea | 10 (1.1) | 28 (1.9) | 6 (1.0) |
| Myalgia | 3 (0.3) | 26 (1.7) | 4 (0.7) |
| Injection site reactions (pain, erythema, bruising, hemorrhage, pruritus) | 11 (1.3) | 23 (1.5) | 12 (2.0) |
| Influenza | 4 (0.5) | 19 (1.3) | 7 (1.1) |
| Neutropenia | 4 (0.5) | 15 (1.0) | 5 (0.8) |
| Tinea infections (tinea pedis, versicolor, cruris) | 2 (0.2) | 15 (1.0) | 3 (0.5) |
| a subjects receiving 210 mg of SILIQ at Weeks
0, 1, and 2, followed by treatment every two weeks during the 12-week period b Trials 2 and 3 included the active comparator, ustekinumab. |
|||
Adverse reactions that occurred in less than 1% of subjects in the SILIQ group through Week 12 were conjunctivitis and candida infections (including oral [0.2%], genital [0.1%], and esophageal [0.1%] versus none in the placebo group).
Week 0 to End of Trial: Through Week 52, exposure-adjusted rates of serious adverse events were similar between subjects treated with SILIQ and those treated with ustekinumab. Through the end of the trial, the exposure-adjusted rates of treatment-emergent serious adverse events were similar to those seen in the 52-week period in the subjects treated with SILIQ.
During the 12-week randomized treatment period in the pooled trials, one subject in the SILIQ group attempted suicide and none in the placebo or ustekinumab groups. From initiation through Week 52 of the trials, suicidal ideation or behavior occurred in 7 of 4019 subjects (0.2 per 100 subject-years) treated with SILIQ and in 2 of 613 subjects (0.4 per 100 subject-years) treated with ustekinumab.
During the course of the clinical trials for plaque psoriasis, suicidal ideation or behavior occurred in 34 of 4464 subjects treated with SILIQ (0.37 per 100 subject-years). Eight of the 10 subjects who attempted or completed suicide had a history of depression and/or suicidal ideation or behavior [see WARNINGS AND PRECAUTIONS].
During the 12-week randomized treatment period, infections occurred in 25.4% of the SILIQ group compared to 23.4% of the placebo group. The majority of infections consisted of nasopharyngitis, upper respiratory tract infection, pharyngitis, urinary tract infections, bronchitis, and influenza, and did not necessitate treatment discontinuation. The SILIQ group had a higher rate of fungal infections compared to the placebo group (1.8% vs 0.9%). The fungal infections were primarily non-serious skin and mucosal candida infections [see WARNINGS AND PRECAUTIONS].
During the 12-week randomized treatment period, neutropenia occurred in 0.7% of subjects in the SILIQ group. Most adverse reactions of neutropenia were transient. In subjects with normal absolute neutrophil count (ANC) at baseline, a reduction in ANC occurred in 6.8% of subjects in the SILIQ group, compared to 3.3% in the ustekinumab group, and 3.6% in the placebo group. Neutropenia ≥ Grade 3 ( < 1000/mm²) occurred in 0.5% of subjects in the SILIQ group compared to 0.2% of subjects in the ustekinumab group and none in the placebo group. From Week 0 to end of trial, the exposure-adjusted rate of treatment-emergent neutropenia was 0.4 per 100 subject-years (0.1 per 100 subject-years were ≥ Grade 3). No serious infections were associated with cases of neutropenia.
As with all therapeutic proteins, there is potential for immunogenicity with SILIQ. Approximately 3% of subjects treated with SILIQ developed antibodies to brodalumab through the 52-week treatment period. Of the subjects who developed antibodies to brodalumab, none had antibodies that were classified as neutralizing. However, the assay to test for neutralizing antibodies had limitations detecting neutralizing antibodies in the presence of brodalumab; therefore, the incidence of neutralizing antibody development could be underestimated.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to SILIQ with the incidence of antibodies to other products may be misleading.
Avoid use of live vaccines in patients treated with SILIQ [see WARNINGS AND PRECAUTIONS].
The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e.g., IL-1, IL-6, IL-10, TNFα, IFN) during chronic inflammation. Treatment with SILIQ may modulate serum levels of some cytokines.
Therefore, upon initiation or discontinuation of SILIQ in patients who are receiving concomitant drugs which are CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate [see CLINICAL PHARMACOLOGY].
Included as part of the PRECAUTIONS section.
Suicidal ideation and behavior, including 4 completed suicides, occurred in subjects treated with SILIQ in the psoriasis clinical trials. There were no completed suicides in the 12-week placebo-controlled portion of the trials. SILIQ users with a history of suicidality or depression had an increased incidence of suicidal ideation and behavior as compared to users without such a history [see ADVERSE REACTIONS]. A causal association between treatment with SILIQ and increased risk of suicidal ideation and behavior has not been established.
Prescribers should weigh the potential risks and benefits before using SILIQ in patients with a history of depression or suicidality. Patients with new or worsening symptoms of depression or suicidality should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, anxiety, or other mood changes. Prescribers should also reevaluate the risks and benefits of continuing treatment with SILIQ if such events occur.
Because of the observed suicidal ideation and behavior in subjects treated with SILIQ, if an adequate response to SILIQ has not been achieved within 12 to 16 weeks, consider discontinuing therapy.
SILIQ is available only through a restricted program under a REMS [see SILIQ REMS Program].
SILIQ is available only through a restricted program under a REMS called the SILIQ REMS Program because of the observed suicidal ideation and behavior in subjects treated with SILIQ [see Suicidal Ideation And Behavior].
Notable requirements of the SILIQ REMS Program include the following:
Further information, including a list of qualified pharmacies, is available at www.SILIQREMS.com or by calling the SILIQ REMS Program Call Center at 855-511-6135.
SILIQ may increase the risk of infections. In clinical trials, subjects treated with SILIQ had a higher rate of serious infections than subjects treated with placebo (0.5% versus 0.2%) and higher rates of fungal infections (2.4% versus 0.9%). One case of cryptococcal meningitis occurred in a subject treated with SILIQ during the 12-week randomized treatment period and led to discontinuation of therapy [see ADVERSE REACTIONS].
During the course of clinical trials for plaque psoriasis, the exposure-adjusted rates for infections and serious infections were similar in the subjects treated with SILIQ and those treated with ustekinumab.
In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SILIQ. Instruct patients to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy for the infection, monitor the patient closely and discontinue SILIQ therapy until the infection resolves.
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SILIQ. Do not administer SILIQ to patients with active TB infection. Initiate treatment for latent TB prior to administering SILIQ.
Consider anti-TB therapy prior to initiation of SILIQ in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients receiving SILIQ for signs and symptoms of active TB during and after treatment.
In psoriasis trials, which excluded subjects with active Crohn's disease, Crohn's disease occurred in one subject during treatment with SILIQ and led to discontinuation of therapy. In other trials, exacerbation of Crohn's disease was observed with SILIQ use.
SILIQ is contraindicated in patients with Crohn's disease.
Discontinue SILIQ if the patient develops Crohn's disease while taking SILIQ.
Avoid use of live vaccines in patients treated with SILIQ. No data are available on the ability of live or inactive vaccines to elicit an immune response in patients being treated with SILIQ.
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use) before the patient starts using SILIQ, and each time the prescription is renewed, as there may be new information they need to know.
Instruct patients and their caregivers to monitor for the emergence of suicidal thoughts and behavior and promptly seek medical attention if the patient experiences suicidal thoughts, new or worsening depression, anxiety, or other mood changes [see WARNINGS AND PRECAUTIONS].
Instruct patients to carry the wallet card provided and to call the National Suicide Prevention Lifeline at 1-800-273-8255 if they experience suicidal thoughts.
Because of the observed suicidal thoughts and behavior in subjects treated with SILIQ, SILIQ is available only through a restricted program called the SILIQ REMS Program [see WARNINGS AND PRECAUTIONS]. Inform the patient of the following:
SILIQ is available only from certified pharmacies participating in the program. Therefore, provide patients with the telephone number and website for information on how to obtain the product.
Inform patients that SILIQ may lower the ability of their immune system to fight infections. Instruct patients of the importance of communicating any history of infections to their healthcare providers and to contact their healthcare providers if they develop any signs or symptoms of infection [see WARNINGS AND PRECAUTIONS].
Instruct patients to seek medical advice if they develop signs and symptoms of Crohn's disease [see WARNINGS AND PRECAUTIONS].
Instruct the patient to perform the first self-injection under the guidance and supervision of a qualified healthcare professional for proper training in subcutaneous injection technique. Instruct patients who are self-administering to inject the full dose of SILIQ [see DOSAGE AND ADMINISTRATION and Instructions for Use]. Instruct patients or caregivers in the technique of proper syringe and needle disposal [see Instructions for Use].
Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of SILIQ. The published literature is mixed on the potential effects on malignancy risk due to the inhibition of the IL-17RA, the pharmacological action of SILIQ. Some published literature suggests that IL-17A directly promotes cancer cell invasion, which suggests a potential beneficial effect of SILIQ. However, other reports indicate IL-17A promotes T-cell mediated tumor rejection, which suggests a potential adverse effect by SILIQ. However, inhibition of the IL-17RA with SILIQ has not been studied in these models. Therefore, the relevance of experimental findings in these models for malignancy risk in humans is unknown.
In cynomolgus monkeys, there were no effects on fertility parameters such as changes in reproductive organs or sperm analysis following subcutaneous administration of brodalumab at dose levels up to 90 mg/kg/week for six months (26 times the MRHD on a mg/kg basis). The monkeys were not mated in this study to evaluate effects on fertility.
There are no human data on SILIQ use in pregnant women to inform a drug associated risk. Human IgG antibodies are known to cross the placental barrier; therefore, SILIQ may be transmitted from the mother to the developing fetus. In a combined embryofetal development and pre-and post-natal development study, no adverse developmental effects were observed in infants born to pregnant monkeys after subcutaneous administration of brodalumab during organogenesis through parturition at doses up to 26 times the maximum recommended human dose (MRHD)[see Data].
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Animal Data
A combined embryofetal development and pre-and post-natal development study was conducted in cynomolgus monkeys administered brodalumab. No brodalumab-related effects on embryofetal toxicity or malformations, or on morphological, functional or immunological development were observed in infants from pregnant monkeys administered weekly subcutaneous doses of brodalumab up to 26 times the MRHD from the beginning of organogenesis to parturition (on a mg/kg basis of 90 mg/kg/week).
There are no data on the presence of brodalumab in human milk, the effects on the breastfed infant, or the effects on milk production. Brodalumab was detected in the milk of lactating cynomolgus monkeys. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SILIQ and any potential adverse effects on the breastfed infant from SILIQ or from the underlying maternal condition.
The safety and effectiveness of SILIQ have not been evaluated in pediatric patients.
Of the 3066 plaque psoriasis subjects initially randomized to SILIQ in clinical trials, 192 (6%) were ≥ 65 years old and no subjects were ≥ 75 years old. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 years and older was not sufficient to determine whether they responded differently from younger subjects [see CLINICAL PHARMACOLOGY].
No information provided.
SILIQ is contraindicated in patients with Crohn's disease because SILIQ may cause worsening of disease [see WARNINGS AND PRECAUTIONS].
Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines.
Elevated levels of IL-17A, IL-17C and IL-17F are found in psoriatic plaques. Serum IL-17A levels, measured at Weeks 12, 24, and 48 of SILIQ 210 mg every 2 weeks of treatment, were higher than the baseline levels in subjects with moderate to severe plaque psoriasis. The relationship between the pharmacodynamic activity and the mechanism(s) by which brodalumab exerts its clinical effects is unknown.
Following a single subcutaneous dose of 210 mg in subjects with plaque psoriasis, brodalumab reached peak mean (±SD) serum concentration (Cmax) of 13.4±7.3 mcg/mL by approximately 3 days post dose. The mean (±SD) area-under-theconcentration-time curve (AUC) of brodalumab was 111±64 mcg•day/mL.
Following multiple subcutaneous doses of 210 mg every 2 weeks, steady-state was achieved by Week 4. The mean (±SD) Cmax was 20.6±14.6 mcg/mL and the mean (±SD) AUC over the two week dosing interval was 227±167 mcg•day/mL.
Following subcutaneous administration, brodalumab bioavailability was approximately 55%.
Following a single subcutaneous administration of brodalumab 210 mg in subjects with plaque psoriasis, the mean (±SD) apparent volume of distribution (Vz/F) of brodalumab was 8.9±9.4 L.
The metabolic pathway of brodalumab has not been characterized. As a human monoclonal IgG2 antibody, brodalumab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG.
Following a single subcutaneous administration of brodalumab 210 mg in subjects with plaque psoriasis, the mean (±SD) apparent total clearance (CL/F) was 3.0±3.5 L/day. The clearance of brodalumab increased with decreasing doses due to nonlinear elimination.
Brodalumab exhibited non-linear pharmacokinetics with exposures that increased greater than dose-proportionally over a dose range from 140 mg (approximately 0.67 times the recommended dose) to 350 mg (approximately 1.67 times the recommended dose) following subcutaneous administrations in subjects with plaque psoriasis.
Brodalumab trough concentrations were lower in subjects with higher body weight.
No trials were conducted to assess the effect of hepatic or renal impairment on the pharmacokinetics of brodalumab.
Population pharmacokinetic analysis indicated that age did not significantly influence the clearance of brodalumab in subjects with plaque psoriasis. Subjects who were 65 years or older had a similar brodalumab clearance as compared to subjects less than 65 years old.
In subjects with plaque psoriasis, one week following a single subcutaneous administration of 210 mg brodalumab, the exposure of midazolam (CYP3A4 substrate) was increased by 24% [see DRUG INTERACTIONS].
Three multicenter, randomized, double-blind, controlled trials (Trials 1, 2, and 3) enrolled a total of 4373 subjects 18 years of age and older with at least a 6-month history of moderate to severe plaque psoriasis, defined as having a minimum affected body surface area (BSA) of 10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12, a static Physician's Global Assessment (sPGA) score ≥ 3 in the overall assessment (plaque thickness/induration, erythema, and scaling) of psoriasis on a severity scale of 0 to 5, and who were candidates for systemic therapy or phototherapy. In all three trials, subjects were randomized to subcutaneous treatment with placebo or SILIQ 210 mg at Weeks 0, 1, and 2, followed by treatments every 2 weeks [Q2W] through Week 12. In the two active comparator trials (Trials 2 and 3), subjects randomized to ustekinumab received a 45 mg dose if their weight was less than or equal to 100 kg and a 90 mg dose if their weight was greater than 100 kg at Weeks 0, 4, and 16, followed by the same dose every 12 weeks.
All three trials assessed the change from baseline to Week 12 compared to placebo in the two co-primary endpoints: 1) PASI 75, the proportion of subjects who achieved at least a 75% reduction in the PASI composite score that takes into consideration both the percentage of body surface area affected and the nature and severity of psoriatic changes (induration, erythema, and scaling) within the affected region, and 2) the proportion of subjects with an sPGA of 0 (clear) or 1 (almost clear), and at least a 2-point improvement from baseline. In Trials 2 and 3, comparisons were also made to ustekinumab for the primary endpoint of the proportion of subjects who achieved a reduction in PASI score of 100% (PASI 100) from baseline at Week 12.
Other evaluated outcomes included the proportion of subjects who achieved an sPGA of 0 (clear) at Week 12, and the proportion of subjects who achieved a Psoriasis Symptom Inventory (PSI) score of 0 (not at all) or 1 (mild) on every item (itch, redness, scaling, burning, stinging, cracking, flaking, and pain) at Week 12. Baseline demographics and disease characteristics were generally consistent across all treatment groups in all three trials. Subjects were predominantly men (69%) and white (91%), with a mean age of 45 years. The mean baseline body weight was 90.5 kg and 28% of subjects had body weight greater than 100 kg. The baseline PASI score ranged from 9.4 to 72 (median: 17.4) and the baseline affected BSA ranged from 10 to 97% (median: 21%). Baseline sPGA scores ranged from “3 (moderate)” (58%) to “5 (very severe)” (5%).
Approximately 21% of subjects had a history of psoriatic arthritis. Approximately 30% of subjects had previously received a biologic therapy and 12% of subjects had failed previous biologic therapy.
The results of Trials 1, 2, and 3 are presented in Table 2.
Table 2: Efficacy Results at Week 12 in Adults with
Plaque Psoriasis in Trials 1, 2, and 3 (NRIa)
| Endpoint | Trial 1 | Trial 2 | Trial 3 | |||||
| SILIQ 210 mg Q2W (N=222) n (%) |
Placebo (N=220) n (%) |
SILIQ 210 mg Q2W (N=612) n (%) |
Ustekinumab (N=300) n (%) |
Placebo (N=309) n (%) |
SILIQ 210 mg Q2W (N=624) n (%) |
Ustekinumab (N=313) n (%) |
Placebo (N=315) n (%) |
|
| PASI 75b response | 185(83) | 6 (3) | 528(86) | 210(70) | 25 (8) | 531(85) | 217 (69) | 19 (6) |
| PASI 100 response | 93 (42) | 1 ( < 1) | 272 (44) b | 65(22) | 2 (1) | 229 (37) b | 58 (19) | 1 ( < 1) |
| sPGA success clear (0) or almost clear (1)b | 168(76) | 3 (1) | 481(79) | 183 (61) | 12 (4) | 497(80) | 179 (57) | 13 (4) |
| sPGA of clear (0) | 93 (42) | 1 ( < 1) | 274 (45) | 65 (21) | 2 (1) | 229 (37) | 58(19) | 1 ( < 1) |
| aNRI = non-responder imputation bCo-primary endpoints |
||||||||
Examination of age, gender, race, use of prior systemic or phototherapy, and use of prior biologics did not identify differences in response to SILIQ among these subgroups.
At Week 12, compared to subjects in the placebo group, a greater proportion of subjects in SILIQ 210 mg Q2W group achieved a Psoriasis Symptom Inventory (PSI) score of 0 (not at all) or 1 (mild) on every item (itch, redness, scaling, burning, stinging, cracking, flaking, pain).
In Trial 1, subjects randomized to receive SILIQ and who were responders at Week 12 (i.e., sPGA of 0 or 1) were re-randomized to receive either placebo or SILIQ. Among responders at Week 12, 83% (69/83) of subjects re-randomized to continued treatment with SILIQ 210 mg Q2W maintained this response (sPGA of 0 or 1) at Week 52 compared to none (0/84) who were re-randomized to placebo and withdrawn from SILIQ. In addition, 87% (72/83) of subjects re-randomized to continued treatment with SILIQ 210 mg Q2W achieved PASI 75 response at Week 52 compared to none (0/84) who were re-randomized to placebo and withdrawn from SILIQ.
Trials 2 and 3 included a re-randomized phase during which subjects originally randomized to receive SILIQ during the first 12 weeks were re-randomized to one of four SILIQ regimens at the Week 12 visit and placebo subjects were crossed over to receive SILIQ 210 mg Q2W. Subjects receiving ustekinumab continued the same treatment until crossed over at Week 52 to SILIQ 210 mg Q2W. For sPGA 0 or 1 responders at Week 12, the percentage of subjects who maintained this response at Week 52 was 79% for subjects treated with SILIQ 210 mg Q2W. For PASI 100 responders at Week 12, 72% of the subjects who continued on SILIQ 210 mg Q2W maintained the response at Week 52.
SILIQ™
(SIL-EEK)
(brodalumab) Injection, For Subcutaneous Use
What is the most important information I should know about SILIQ?
SILIQ may cause serious side effects, including:
Your healthcare provider will give you a SILIQ Patient Wallet Card about symptoms you should get medical help for right away. Carry the card with you at all times during treatment with SILIQ and show it to all of your healthcare providers.
See “What are the possible side effects of SILIQ?” for more information about side effects.
What is SILIQ?
SILIQ is a prescription medicine used to treat adults with moderate to severe plaque psoriasis:
It is not known if SILIQ is safe and effective in children.
Do not use SILIQ if you have Crohn's disease.
Before you use SILIQ, tell your healthcare provider about all of your medical conditions, including if you:
How should I use SILIQ?
What are the possible side effects of SILIQ?
SILIQ may cause serious side effects. See “What is the most important information I should know about SILIQ?”
The most common side effects of SILIQ include: joint pain, headache, tiredness, diarrhea, mouth or throat pain, nausea, muscle pain, injection site reactions, flu (influenza), low white blood count (neutropenia), and fungal infections of the skin. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about safe and effective use of SILIQ
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use SILIQ for a condition for which it was not prescribed. Do not give SILIQ to other people even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about SILIQ that is written for health professionals.
Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA Manufactured by: Valeant Pharmaceuticals Luxembourg S.à.r.l., Grand Duchy of Luxembourg, L-1931, Luxembourg U.S. Issued: February/2017
Instructions for Use
SILIQ is supplied as a single-dose prefilled syringe. Each prefilled syringe contains one 210 mg dose of SILIQ. Each SILIQ prefilled syringe can only be used one time.
Your healthcare provider has prescribed SILIQ and will tell you how often it should beinjected. If your healthcare provider decides that you or a caregiver may be able to give your injections of SILIQ at home, you should receive training on the right way to prepare and inject SILIQ. Do not try to inject yourself until you have been shown the right way to give the injections by your healthcare provider.
Read all of the instructions before using the SILIQ prefilled syringe. Call your healthcare provider if you or your caregiver have any questions about the right way to inject SILIQ.
Instructions for Use
SILIQ™
(SIL-EEK)
(brodalumab) Injection, For Subcutaneous Use
Single-Dose Prefilled Syringe
Guide to parts
 |
Important
Storing your SILIQ prefilled syringe
Using your SILIQ prefilled syringe
Step 1: Prepare
A. Remove one SILIQ prefilled syringe from the package.
Grab the syringe by the barrel to remove the prefilled syringe from the tray.
 |
Place your finger or thumb on the edge of the tray to hold it while you remove the prefilled syringe.
Put the original package with any unused prefilled syringes back in the refrigerator.
For safety reasons:
Wait about 30 minutes to let the prefilled syringe warm to room temperature before you use it.
B. Inspect the SILIQ prefilled syringe.
 |
Make sure the medicine in the prefilled syringe is clear and colorless to slightly yellow.
In all cases, use a new prefilled syringe, and call 1-800-321-4576.
C Gather all materials needed for your injection.
Wash your hands thoroughly with soap and water.
On a clean, well-lit work surface, place the:
 |
D. Prepare and clean your injection site.
 |
You can use:
Clean your injection site with an alcohol wipe. Let your skin dry.
Avoid injecting directly into raised, thick, red, or scaly skin patch or lesion.
Step 2: Get ready
E. Pull the gray needle cap straight off and away from your body when you are ready to inject.
 |
It is normal to see a drop of liquid at the end of the needle.
Important: Throw the needle cap into the sharps disposal container provided.
F. Pinch your injection site to create a firm surface.
 |
Pinch skin firmly between your thumb and fingers, creating an area about 2 inches wide.
Important: Keep skin pinched while injecting.
Step 3: Inject
G. Hold the pinch. Insert the needle into your skin at 45 to 90 degrees.
 |
Do not place your finger on the plunger rod while inserting the needle.
H. Using slow and constant pressure, push the plunger rod all the way down until it reaches the bottom.
 |
I. When done, release your thumb, and gently lift the syringe and pull the needle out of your skin.
 |
J Inspect the syringe. If there is still medicine in the syringe barrel, this means you have not received a full dose. Call your healthcare provider right away.
Step 4: Finish
K. Discard (throw away) the used syringe.
 |
Important: Always keep the sharps disposal container out of the reach of children.
L Examine the injection site.
If there is blood, press a cotton ball or gauze pad on your injection site. Do not rub the injection site. Apply an adhesive bandage if needed.
